Biotech startups that raised Series A in Boston, Massachusetts
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Dash Bio | Boston | Series A | $30.0M | 2026-08-03 |
| Third Arc Bio | Boston | Series A | $52.0M | 2026-02-04 |
| Neurable | Boston | Series A | $35.0M | 2025-12-19 |
| AI Proteins | Boston | Series A | $42.5M | 2025-11-19 |
| Predicta Biosciences | Boston | Series A | $23.4M | 2025-10-01 |
| Folia Health | Boston | Series A | $10.5M | 2025-10-01 |
| Freya Biosciences | Boston | Series A | $11.8M | 2024-11-19 |
| Averna Therapeutics | Boston | Series A | $85.0M | 2024-06-25 |
8 rows of the CSV in 5 of its 18 columns.
- The 57 biotech startups in Boston, Massachusetts whose last round is Series A have raised $2.8B in total.
- 13 of them closed their most recent round in the last 12 months, $672.6M combined.
- The largest of those rounds is Solstice Oncology's $225.0M Series A, dated September 2026.
- The most recent is Signet Therapeutics' $11.5M Series A on 4 November 2026.
- MassChallenge is an investor in 3 of them, more than any other fund.
- Health care is the most common other sector, with 48 companies (84%).
- 45% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 11 to 50 employees (63% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
8 of 57| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
| Folia Health | Folia Health is a platform that securely captures and shares users' health and symptom data. | Biotech | Series A | $10.5M | 2025-10-01 | $17.4M | MassChallenge, Social Starts, Bantam Group +2 | 11 to 50 | 2016 |
| Adaptilens | Adaptilens develops an accommodating intraocular lens for cataract patients. | Biotech | Series A | $17.5M | 2024-04-29 | $19.1M | MassChallenge, Pillar VC, Perceptive Advisors +2 | 1 to 10 | 2019 |
| Ascidian Therapeutics | Ascidian Therapeutics is a biotechnology company focused on medical and clinical gene therapy. | Biotech | Series A | $40.0M | 2023-11-08 | $90.0M | Apple Tree Partners | 11 to 50 | 2020 |
| Orbita | Orbita sells voice-first and conversational AI software that helps patients engage with digital healthcare. | Artificial intelligence | Series A | $9.0M | 2020-05-27 | $16.5M | MassChallenge, nvp capital, Cultivation Capital +2 | 11 to 50 | 2015 |
Table 1. Biotech startups that raised Series A in Boston, Massachusetts: the 8 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 57.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| 2 | AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
| 3 | Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| 4 | Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
Table 2. Biotech startups that raised Series A in Boston, Massachusetts: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | MassChallenge | Startup accelerator | Boston, United States | 3 | 5% | ||
| 2 | firedrop | Micro VC fund | London, United Kingdom | 1 | 2% | 1 | Dash Bio |
| 3 | LifeX Ventures | Venture capital firm | New York, United States | 1 | 2% | 1 | Dash Bio |
| 4 | Swift Ventures | Venture capital firm | Lafayette, United States | 1 | 2% | 1 | Dash Bio |
| 5 | Freestyle Capital | Venture capital firm | San Francisco, United States | 1 | 2% | 1 | Dash Bio |
| 6 | Cormorant Asset Management | Hedge fund | Boston, United States | 1 | 2% | 1 | Third Arc Bio |
| 7 | T. Rowe Price | Private equity firm | Baltimore, United States | 1 | 2% | 1 | Third Arc Bio |
| 8 | AbbVie | Corporate venture arm | North Chicago, United States | 1 | 2% | 1 | Third Arc Bio |
| 9 | Foresite Capital | Private equity firm | San Francisco, United States | 1 | 2% | 1 | Third Arc Bio |
| 10 | Metaplanet | Venture capital firm | Tallinn, Estonia | 1 | 2% | 1 | Neurable |
| 11 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 1 | 2% | 1 | Neurable |
| 12 | M Ventures | Corporate venture arm | Amsterdam, The Netherlands | 1 | 2% | 1 | Neurable |
| 13 | Global Brain Corporation | Venture capital firm | Tokyo, Japan | 1 | 2% | 1 | Neurable |
| 14 | Intel Ignite | Startup accelerator | Tel Aviv, Israel | 1 | 2% | 1 | AI Proteins |
| 15 | Cobro Ventures | Private equity firm | Arlington, United States | 1 | 2% | 1 | AI Proteins |
Table 3. Biotech startups that raised Series A in Boston, Massachusetts: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 48 | 84% | $2.4B |
| Software | 11 | 19% | $354.8M |
| Artificial intelligence | 9 | 16% | $307.4M |
| Hardware | 3 | 5% | $121.8M |
| Commerce | 1 | 2% | $17.0M |
| Energy | 1 | 2% | $5.8M |
Table 4. Biotech startups that raised Series A in Boston, Massachusetts by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 57 | 100% | $34.0M |
Table 5. Biotech startups that raised Series A in Boston, Massachusetts by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 8% | $11.5M |
| October 2026 | 1 | 8% | $30.0M |
| September 2026 | 2 | 15% | $235.0M |
| August 2026 | 1 | 8% | $30.0M |
| June 2026 | 2 | 15% | $46.6M |
| February 2026 | 1 | 8% | $52.0M |
| January 2026 | 1 | 8% | $80.0M |
| December 2025 | 2 | 15% | $55.0M |
| November 2025 | 2 | 15% | $132.5M |
Table 6. Biotech startups that raised Series A in Boston, Massachusetts: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 9 | 16% | $485.1M |
| 2025 | 9 | 16% | $506.4M |
| 2024 | 7 | 12% | $367.0M |
| 2023 | 5 | 9% | $85.6M |
| 2022 | 4 | 7% | $117.0M |
| 2021 | 6 | 11% | $228.1M |
Table 7. Biotech startups that raised Series A in Boston, Massachusetts by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 9 | 16% |
| 2020 to 2022 | 16 | 29% |
| 2015 to 2019 | 23 | 41% |
| 2010 to 2014 | 5 | 9% |
| Before 2010 | 3 | 5% |
Table 8. Biotech startups that raised Series A in Boston, Massachusetts by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 17 | 30% |
| 11 to 50 | 36 | 63% |
| 51 to 100 | 1 | 2% |
| 101 to 250 | 2 | 4% |
| 251 to 500 | 1 | 2% |
Table 9. Biotech startups that raised Series A in Boston, Massachusetts by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Boston, Massachusetts. On 16 November 2026 that is 57 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 8 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 57 rows: 6 have no round amount, 0 no city and 6 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Boston, Massachusetts whose last round is Series A are on the list?
- 57, in the file dated 16 November 2026. 13 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 57 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.